Publications by authors named "Donald Stanski"

Claim this Profile
S
Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19.
Yuri Kosinsky, Kirill Peskov, Donald R Stanski, Diana Wetmore, Joseph Vinetz

Microbiol Spectr· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Titration Paradox Turns Pharmacology Upside Down.
Steven L Shafer, Donald R Stanski

Clin Pharmacol Ther· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating dose estimation into a decision-making framework for model-based drug development.
James Dunyak, Patrick Mitchell, Bengt Hamrén, Gabriel Helmlinger, James Matcham, Donald Stanski

Pharm Stat· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics.
Sergey Aksenov, Carl C Peck, Ulf G Eriksson, Donald R Stanski

Physiol Rep· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model.
Yuri Kosinsky, Simon J Dovedi, Kirill Peskov, Veronika Voronova, Lulu Chu, Donald R Stanski

J Immunother Cancer· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meet.
Gabriel Helmlinger, Nidal Al-Huniti, Sergey Aksenov, Kirill Peskov, Karen M Hallow, Donald Stanski

Eur J Pharm Sci· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction.
Daniel Röshammar, Joakim Nyberg, Tomas Andersson, Donald Stanski, Robert F Storey

J Clin Pharmacol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach.
Nelleke Snelder, Bart A Ploeger, Olivier Luttringer, Dean F Rigel, Randy L Webb, Donald R Stanski

J Pharmacol Exp Ther· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational pharmacokinetic modeling of fingolimod (FTY720) as a paradigm compound subject to sphingosine kinase-mediated phosphorylation.
Nelleke Snelder, Bart A Ploeger, Olivier Luttringer, Donald R Stanski, Meindert Danhof

Drug Metab Dispos· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment on the report "limitations of model-based dose selection for indacaterol in patients with chronic obstructive pulmonary disease".
Michael Looby, Didier Renard, Andrew Wright, David Morris, Donald Stanski

Int J Clin Pharmacol Ther· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Innovative approaches to clinical development and trial design.
John J Orloff, Donald Stanski

Ann Ist Super Sanita· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches.
Didier Renard, Michael Looby, Benjamin Kramer, David Lawrence, David Morris, Donald R Stanski

Respir Res· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding pharmacokinetics using realistic computational models of fluid dynamics: biosimulation of drug distribution within the CSF space for intrathecal drugs.
Andreas Kuttler, Thomas Dimke, Steven Kern, Gabriel Helmlinger, Donald Stanski

J Pharmacokinet Pharmacodyn· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fostering culture and optimizing organizational structure for implementing model-based drug development.
Liping Zhang, Sandra R Allerheiligen, Richard L Lalonde, Donald R Stanski, Marc Pfister

J Clin Pharmacol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The future of drug development: advancing clinical trial design.
John Orloff, Frank Douglas, Jose Pinheiro, Susan Levinson, Michael Branson, Donald Stanski

Nat Rev Drug Discov· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Communicating with the FDA: the "third rail" of a new model for drug development.
Donald R Stanski, John J Orloff

J Clin Pharmacol· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current issues relating to drug safety especially with regard to the use of biomarkers: a meeting report and progress update.
Paul Rolan, Meindert Danhof, Donald Stanski, Carl Peck

Eur J Pharm Sci· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enriched analgesic efficacy studies: an assessment by clinical trial simulation.
Hendrikus J M Lemmens, D Russell Wada, Catherine Munera, Ahmed Eltahtawy, Donald R Stanski

Contemp Clin Trials· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inadequate anaesthesia in lethal injection for execution.
Mark J S Heath, Donald R Stanski, Derrick J Pounder

Lancet· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Getting the Dose Right: report from the Tenth European Federation of Pharmaceutical Sciences (EUFEPS) conference on optimizing drug development.
Donald R Stanski, Malcolm Rowland, Lewis B Sheiner

J Pharmacokinet Pharmacodyn· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers.
David R Drover, Martin S Angst, Marta Valle, Bhamini Ramaswamy, Sujata Naidu, Donald R Stanski

Anesthesiology· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis